Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.

@article{Rosenberg2008PhaseIS,
  title={Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.},
  author={Jonathan E Rosenberg and Susan Halabi and Ben L Sanford and Andrew L Himelstein and James Norman Atkins and Raymond J. Hohl and Frederick Millard and Dean F Bajorin and Eric Jay Small},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2008},
  volume={19 5},
  pages={946-50}
}
BACKGROUND There is no standard second-line treatment for advanced urothelial carcinoma (UC). Response rates to second-line chemotherapy for advanced UC are low and response duration is short. Bortezomib is a proteasome inhibitor with preclinical activity against UC. PATIENTS AND METHODS Treatment consisted of bortezomib 1.3 mg/m(2) i.v. twice weekly for… CONTINUE READING